Capitalizing R&D: How Ind AS Differs from US GAAP#
For technology startups and pharmaceutical giants, R&D is the largest expense. The accounting treatment heavily impacts reported profitability. This is a critical area where India's Ind AS 38 (Intangible Assets) provides significantly more flexibility than US GAAP.
The US GAAP Approach: Expense Everything#
FASB argues that the future economic benefits of R&D are inherently highly uncertain. Therefore, under US GAAP: Almost all R&D costs must be expensed immediately on the P&L as incurred. This destroys short-term profitability.
The Ind AS (IFRS) Approach: The Split Phase#
Ind AS 38 splits R&D into two distinct phases:
- The Research Phase: All Research costs must be expensed immediately, as you don't know if it will yield a product.
- The Development Phase: Development costs must be capitalized (recorded as an Intangible Asset) if the company can demonstrate 6 strict criteria, including technical feasibility, intention to sell, and probable future economic benefits.
The ability to capitalize development costs is a massive lifeline for Indian tech startups. By parking these costs on the balance sheet as an "Intangible Asset under Development," they shield their P&L, showing better EBITDA margins to investors.